Top 4 Cranial Electrotherapy Stimulation Devices Companies

The global cranial electrotherapy stimulation devices market was valued at USD 1.6 billion in 2024. The market is expected to grow at a CAGR of 9.8% during the forecast period of 2025-2034, with the values likely to reach USD 4.1 billion by 2034. The market is driven by rapid technological innovations and robust regulatory support, fueling investor confidence and expanding market opportunities.

Cranial electrotherapy stimulation devices are non-invasive tools that apply low-level electrical currents to the brain using electrodes on the scalp. They are primarily used to treat anxiety, depression, and sleep disorders by modulating neural activity. These devices serve as adjunct therapies, offering an alternative for individuals who do not respond adequately to medications. Clinical research supports their effectiveness and safety, with ongoing studies aimed at expanding their applications. Advances in technology have improved device precision and usability, contributing to their growing adoption in clinical settings.

The cranial electrotherapy stimulation devices market is experiencing steady growth driven by technological advancements and increasing demand for alternative mental health therapies. Market players include established medical device manufacturers and innovative start-ups that are investing in research and development to enhance the safety and efficacy of their devices. Regulatory approvals have further accelerated market expansion, while clinical evidence supports the therapeutic benefits of these devices. Rising awareness of mental health issues and the need for non-pharmacological interventions are additional factors stimulating market growth. Future market trends indicate increased integration of digital health technologies and enhanced patient monitoring capabilities within this dynamic market segment. 

In December 2024, Pulvinar Neuro received FDA Breakthrough Device designation for its closed-loop transcranial alternating current stimulation device to treat major depressive disorder. This recognition highlights the device’s potential for rapid symptom relief and effective non-invasive brain stimulation. Such a breakthrough validates advanced therapeutic approaches in the cranial electrotherapy stimulation devices market.

Let’s explore the profile of top companies leading the global cranial electrotherapy stimulation devices market in 2025.

1.    Medicaid Systems 

Medicaid Systems, headquartered in India, has established itself as a pioneer in innovative medical electronics engineering. The company has earned a reputation for excellence in research and development, backed by an experienced team of biomedical engineers specializing in psychiatry, neurology, cardiology, and physiology. Medicaid Systems is renowned for its high-quality biomedical equipment and exceptional customer service in both domestic and international markets. The company’s Pepose cranial electrotherapy stimulator  machine is a device designed to treat anxiety, depression, and insomnia through user-friendly clip electrodes. This breakthrough product, featuring advanced technology such as auto-adjusted amplitude and pulse duration, reflects its commitment to innovation and leadership in the cranial electrotherapy stimulation devices market.

2.    Soterix Medical Inc.

Soterix Medical Inc., headquartered in New York, United States, was established in 2008. It is a global leader in non-invasive neuromodulation and integrated brain monitoring technology. Soterix Medical is renowned for its advanced cranial electrotherapy stimulation devices, which are critical in both clinical trials and human performance testing. The company’s innovative products, such as its High-Definition transcranial Electrical Stimulation (HD-tES) systems, are designed for precision and ease of use. In April 2024, the company announced the launch of the MxN-GO EEG system, a cutting-edge, wire-free device that combines HD-tES with EEG technology, setting a new standard for mobile neuromodulation research.

3.    Innovative Neurological Devices (Cerevella)

Innovative Neurological Devices, headquartered in Indiana, United States, was established in 2018 and has since become a key player in the cranial electrotherapy stimulation devices market. The company has introduced the Cervella cranial electrotherapy stimulator, an award-winning, patented, and FDA-cleared medical device that offers a non-drug alternative for treating anxiety and insomnia. Cervella is designed to deliver micro pulses of electric current through integrated electrodes in an over-ear headset, allowing patients to receive treatment discreetly during daily activities. This innovative approach not only provides an effective solution for patients who experience adverse effects from traditional drug therapies but also complements cognitive and medication-based treatments. By integrating technology with advanced neuroscience, Innovative Neurological Devices is significantly enhancing treatment options and patient care in the mental health sector.

4.    Mind Alive Inc.

Mind Alive Inc., headquartered in Canada, is one of the key companies in the cranial electrotherapy stimulation devices market. It has a strong presence in the alternative health technology sector,  specializing in designing, manufacturing, and distributing innovative audio-visual entrainment (AVE), cranio-electro stimulation (CES), and transcranial direct current stimulation (tDCS) devices. Mind Alive’s products, including the acclaimed Oasis Pro with tDCS, are crafted to alleviate stress, anxiety, sleep disorders, and chronic pain while enhancing overall well-being. The company is actively involved in clinical research and collaborates with leading academic and medical institutions to validate the efficacy of its devices. Through continuous innovation and adherence to rigorous standards, Mind Alive Inc. has secured a significant position in the cranial electrotherapy stimulation devices market, underpinned by certifications such as CSA, UL, and CE for worldwide use.